Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
10 10 2019
Historique:
pubmed: 19 9 2019
medline: 17 6 2020
entrez: 19 9 2019
Statut: ppublish

Résumé

Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metabolism, which is involved in immunity, neuronal function, and aging. Its implication in pathologies such as cancer and neurodegenerative diseases has stimulated the development of IDO1 inhibitors. However, negative phase III clinical trial results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of the role and the mechanisms of IDO1 inhibition. In this work, we investigate the molecular inhibition mechanisms of four known IDO1 inhibitors and of two quinones in detail, using different experimental and computational approaches. We also determine for the first time the X-ray structure of the highly efficient 1,2,3-triazole inhibitor MMG-0358. Based on our results and a comprehensive literature overview, we propose a classification scheme for IDO1 inhibitors according to their inhibition mechanism, which will be useful for further developments in the field.

Identifiants

pubmed: 31525930
doi: 10.1021/acs.jmedchem.9b00942
doi:

Substances chimiques

Enzyme Inhibitors 0
Indoleamine-Pyrrole 2,3,-Dioxygenase 0
Oximes 0
Quinones 0
Recombinant Proteins 0
Sulfonamides 0
Triazoles 0
epacadostat 71596A9R13

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8784-8795

Auteurs

Ute F Röhrig (UF)

Molecular Modeling Group , SIB Swiss Institute of Bioinformatics , 1015 Lausanne , Switzerland.

Aline Reynaud (A)

Protein Production and Structure Core Facility, School of Life Sciences , École Polytechnique Fédérale de Lausanne (EPFL) , 1015 Lausanne , Switzerland.

Somi Reddy Majjigapu (SR)

Molecular Modeling Group , SIB Swiss Institute of Bioinformatics , 1015 Lausanne , Switzerland.
Laboratory of Glycochemistry and Asymmetric Synthesis , École Polytechnique Fédérale de Lausanne (EPFL) , 1015 Lausanne , Switzerland.

Pierre Vogel (P)

Laboratory of Glycochemistry and Asymmetric Synthesis , École Polytechnique Fédérale de Lausanne (EPFL) , 1015 Lausanne , Switzerland.

Florence Pojer (F)

Protein Production and Structure Core Facility, School of Life Sciences , École Polytechnique Fédérale de Lausanne (EPFL) , 1015 Lausanne , Switzerland.

Vincent Zoete (V)

Molecular Modeling Group , SIB Swiss Institute of Bioinformatics , 1015 Lausanne , Switzerland.
Department of Fundamental Oncology , University of Lausanne, Ludwig Lausanne Branch , 1066 Epalinges , Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH